Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16


A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study.

Sierra-Madero JG, Ellenberg S, Rassool MS, Tierney A, Belaunzarán-Zamudio PF, López-Martínez A, Piñeirúa-Menéndez A, Montaner LJ, Azzoni L, Benítez CR, Sereti I, Andrade-Villanueva J, Mosqueda-Gómez JL, Rodriguez B, Sanne I, Lederman MM; CADIRIS study team..

Lancet HIV. 2014 Nov 1;1(2):e60-e67.


Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Kryst J, Kawalec P, Pilc A.

PLoS One. 2015 May 1;10(5):e0124279. doi: 10.1371/journal.pone.0124279. eCollection 2015. Review.


Efficacy and biological safety of lopinavir/ritonavir based anti-retroviral therapy in HIV-1-infected patients: a meta-analysis of randomized controlled trials.

Huang X, Xu Y, Yang Q, Chen J, Zhang T, Li Z, Guo C, Chen H, Wu H, Li N.

Sci Rep. 2015 Feb 23;5:8528. doi: 10.1038/srep08528.


Organic carbamates in drug design and medicinal chemistry.

Ghosh AK, Brindisi M.

J Med Chem. 2015 Apr 9;58(7):2895-940. doi: 10.1021/jm501371s. Epub 2015 Jan 7. Review.


Long-term virological outcome in children on antiretroviral therapy in the UK and Ireland.

Duong T, Judd A, Collins IJ, Doerholt K, Lyall H, Foster C, Butler K, Tookey P, Shingadia D, Menson E, Dunn DT, Gibb DM; Collaborative HIV Paediatric Study Steering Committee..

AIDS. 2014 Oct 23;28(16):2395-405.


48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

Patel DA, Snedecor SJ, Tang WY, Sudharshan L, Lim JW, Cuffe R, Pulgar S, Gilchrist KA, Camejo RR, Stephens J, Nichols G.

PLoS One. 2014 Sep 4;9(9):e105653. doi: 10.1371/journal.pone.0105653. eCollection 2014. Review.


Comparing the efficacy of efavirenz and boosted lopinavir using viremia copy-years.

Lima VD, Sierra-Madero J, Wu Z, Singer J, Wood E, Hull MW, Richard Harrigan P, Montaner JS.

J Int AIDS Soc. 2014 May 6;17:18617. doi: 10.7448/IAS.17.1.18617. eCollection 2014.


The HIV antiretroviral drug efavirenz has LSD-like properties.

Gatch MB, Kozlenkov A, Huang RQ, Yang W, Nguyen JD, González-Maeso J, Rice KC, France CP, Dillon GH, Forster MJ, Schetz JA.

Neuropsychopharmacology. 2013 Nov;38(12):2373-84. doi: 10.1038/npp.2013.135. Epub 2013 May 24.


Deficient reporting and interpretation of non-inferiority randomized clinical trials in HIV patients: a systematic review.

Hernandez AV, Pasupuleti V, Deshpande A, Thota P, Collins JA, Vidal JE.

PLoS One. 2013 May 3;8(5):e63272. doi: 10.1371/journal.pone.0063272. Print 2013. Review.


Evidence for risk stratification when monitoring for toxicities following initiation of combination antiretroviral therapy.

Taiwo B, Yanik EL, Napravnik S, Ryscavage P, Koletar SL, Moore R, Mathews WC, Crane HM, Mayer K, Zinski A, Kahn JS, Eron JJ; CFAR Network of Integrated Clinical Systems (CNICS) Cohort Study..

AIDS. 2013 Jun 19;27(10):1593-602. doi: 10.1097/QAD.0b013e3283601115.


Comparative effectiveness of efavirenz-based antiretroviral regimens in resource-limited settings.

Castillo-Mancilla JR, Campbell TB.

J Comp Eff Res. 2012 Mar;1(2):157-170.


Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users.

Lima VD, Nosyk B, Wood E, Kozai T, Zhang W, Chan K, Montaner JS.

AIDS. 2012 Jul 31;26(12):1491-500. doi: 10.1097/QAD.0b013e3283550b68.


Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?

Kumarasamy N, Patel A, Pujari S.

Indian J Med Res. 2011 Dec;134(6):787-800. doi: 10.4103/0971-5916.92626. Review.


Optimizing initial therapy for HIV infection.

Hull MW, Montaner JS.

J Infect Dis. 2011 Oct 15;204(8):1154-6. doi: 10.1093/infdis/jir506. No abstract available.


Statistical methods in recent HIV noninferiority trials: reanalysis of 11 trials.

Flandre P.

PLoS One. 2011;6(9):e22871. doi: 10.1371/journal.pone.0022871. Epub 2011 Sep 7.


Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.

Dlamini JN, Hu Z, Somaroo H, Highbarger HC, Follmann DA, Dewar RL, Pau AK.

Pharmacotherapy. 2011 Feb;31(2):158-63. doi: 10.1592/phco.31.2.158.

Supplemental Content

Support Center